This study has been designed to compile information on the efficacy of the GliaSite RTS
combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
Data relevant to the evaluation the effectiveness of the GliaSite RTS for a resected
dominant brain metastases will be collected. The GliaSite RTS is a radionuclide applicator
and liquid radionuclide (Iotrex) designed to deliver intracavitary radiation therapy for
resected brain tumors. In this case, it will irradiate the resected margins. Brain
metastases not surgically removed will be then treated with radiosurgery
- Have 1-3 newly diagnosed supratentorial metastatic brain lesions with at least one
being dominant and eligible for surgical resection as visualized on enhanced MRI scan
- Have histological evidence of metastatic carcinoma on intraoperative pathology
(frozen section) or final pathology report
- Have a Karnofsky Performance Status (KPS) >=70
- Have systemic disease which is judged to be stable and has been staged within the
last 6 weeks
- Have a life expectancy of >= 6 month, based upon extent of systemic disease
- Be at least 18 years of age Give informed consent (or have legal representative give
- Be receiving or have plans to receive conventional or investigational systemic agents
for the metastatic brain tumor.
- Be receiving or have plans to receive external beam radiation therapy to the brain.
- Have received prior conventional or investigational systemic agents, including the
use of Gliadel Wafers or Temodar, for the treatment of the brain metastasis.
- Be pregnant or breast-feeding.
- Have uncontrolled hypertension, unstable angina pectoris, evidence of uncontrolled
- Have other serious concurrent infection or other medical illness which would
jeopardize the ability of the patient to safely undergo resection and brachytherapy.
- Have histology of lymphoma or small-cell lung cancer.